Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q1 2026 earnings summary

8 Jul, 2026

Executive summary

  • 1Q26 marked the start of a new growth cycle, with strong sales, margin expansion, and operational improvements aligned with the 2030 plan.

  • Gross revenue grew 15.8% year-over-year to R$1.57 billion, with retail sales up 15.1% and digital channels reaching 28.6% of retail revenue.

  • Adjusted EBITDA rose 25.6% to R$81.2 million, and adjusted net income increased 38.1% to R$38.5 million, reflecting productivity gains and disciplined expense management.

  • Market share in the Southern Region reached a record 13.3%, with gains across all states and categories for the 24th consecutive quarter.

  • Digital sales accounted for 28.5%–28.6% of retail revenue, with app sales up 95.5% year-over-year.

Financial highlights

  • Consolidated gross revenue: R$1,571 million (+15.8% YoY); retail gross revenue: R$1,555–1,560 million (+15.1% YoY).

  • Adjusted EBITDA: R$81.2 million (+25.6% YoY, margin 5.2%).

  • Adjusted net income: R$38.5 million (+38.1% YoY, margin 2.4%).

  • Retail gross margin: 29.4%–29.5% (stable YoY); retail EBITDA margin: 10.7% (+0.8 p.p. YoY).

  • Free cash flow: R$12.4 million, positive for the fifth consecutive quarter.

Outlook and guidance

  • Strategic plan for 2026–2030 underway, targeting R$11.5–12 billion in revenue and 950–1,000 stores by 2030.

  • EBITDA margin guidance between 6.7%–7% for the period.

  • Focus on digitalization, private label expansion, operational efficiency, and customer journey enhancements.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more